Development of Cloned B Cell Populations as Immunotherapeutic Agents Against MYC Carcinogenic Proteins.

IF 4.7 Q2 PHARMACOLOGY & PHARMACY
Advanced pharmaceutical bulletin Pub Date : 2026-06-27 eCollection Date: 2026-09-01 DOI:10.34172/apb.46527
Sushrut Joshi, Chitrali Talele, Gunosindhu Chakraborthy, Manisha Lalan, Sachin Mali
{"title":"Development of Cloned B Cell Populations as Immunotherapeutic Agents Against MYC Carcinogenic Proteins.","authors":"Sushrut Joshi, Chitrali Talele, Gunosindhu Chakraborthy, Manisha Lalan, Sachin Mali","doi":"10.34172/apb.46527","DOIUrl":null,"url":null,"abstract":"<p><p>The MYC proto-oncogene is one of the most extensively dysregulated transcription factors in cancer, governing cell cycle progression, metabolic adaptation, and immune evasion. Despite its central role in tumor biology, MYC has been considered an undruggable target due to its nuclear localization, lack of enzymatic activity, and involvement in transcriptional regulation. The emergence of B-cell based immunotherapies has reshaped the understanding of tumor immunology, revealing that B cells exert both effector and regulatory roles in tumor microenvironment. The intersection between MYC biology and B-cell function is relevant, as MYC is indispensable for B-cell maturation and is frequently dysregulated in B-cell-derived malignancies such as Burkitt lymphoma and diffuse large B-cell lymphoma. We focus specifically on the intersection between MYC-driven oncogenic signaling and emerging B-cell-based immunotherapeutic platforms. This review proposes a conceptual reference framework in which MYC is considered not only as a proliferative driver but also as an immune-modulating oncogene that can aid in the design of humoral therapeutic strategies. Therapeutic strategies to inhibit MYC are systematically discussed, including BET and CDK inhibitors, disruption of MYC-MAX dimerization, RNA-based technologies, synthetic lethality approaches, and emerging PROTACs. Cloned B-cell populations, effector B-cells secreting intrabodies, CAR-B platforms, and antibody-based intracellular targeting are areas of focus. An overview is presented of preclinical and clinical advances made thus far, as well as challenges to the successful translation of these therapies for use in patients including tumor heterogeneity, limitations associated with delivery of agents, and risk of inducing autoimmunity. Forecasting the future provides rationale for combining MYC-targeting agents with immunotherapies and using personalized neoantigen-driven B-cell immunotherapies to treat patients with cancer. Overall, these findings support the concept that MYC B-cell-directed strategies will represent a novel means of treating patients with cancer through their development into new classes of therapeutics.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"16 3","pages":"495-506"},"PeriodicalIF":4.7000,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13745433/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced pharmaceutical bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/apb.46527","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The MYC proto-oncogene is one of the most extensively dysregulated transcription factors in cancer, governing cell cycle progression, metabolic adaptation, and immune evasion. Despite its central role in tumor biology, MYC has been considered an undruggable target due to its nuclear localization, lack of enzymatic activity, and involvement in transcriptional regulation. The emergence of B-cell based immunotherapies has reshaped the understanding of tumor immunology, revealing that B cells exert both effector and regulatory roles in tumor microenvironment. The intersection between MYC biology and B-cell function is relevant, as MYC is indispensable for B-cell maturation and is frequently dysregulated in B-cell-derived malignancies such as Burkitt lymphoma and diffuse large B-cell lymphoma. We focus specifically on the intersection between MYC-driven oncogenic signaling and emerging B-cell-based immunotherapeutic platforms. This review proposes a conceptual reference framework in which MYC is considered not only as a proliferative driver but also as an immune-modulating oncogene that can aid in the design of humoral therapeutic strategies. Therapeutic strategies to inhibit MYC are systematically discussed, including BET and CDK inhibitors, disruption of MYC-MAX dimerization, RNA-based technologies, synthetic lethality approaches, and emerging PROTACs. Cloned B-cell populations, effector B-cells secreting intrabodies, CAR-B platforms, and antibody-based intracellular targeting are areas of focus. An overview is presented of preclinical and clinical advances made thus far, as well as challenges to the successful translation of these therapies for use in patients including tumor heterogeneity, limitations associated with delivery of agents, and risk of inducing autoimmunity. Forecasting the future provides rationale for combining MYC-targeting agents with immunotherapies and using personalized neoantigen-driven B-cell immunotherapies to treat patients with cancer. Overall, these findings support the concept that MYC B-cell-directed strategies will represent a novel means of treating patients with cancer through their development into new classes of therapeutics.

克隆B细胞群作为MYC致癌蛋白免疫治疗剂的研究进展。
MYC原癌基因是癌症中最广泛失调的转录因子之一,控制细胞周期进程、代谢适应和免疫逃避。尽管MYC在肿瘤生物学中发挥着核心作用,但由于其核定位、缺乏酶活性和参与转录调控,MYC一直被认为是一个不可药物的靶标。基于B细胞的免疫疗法的出现重塑了对肿瘤免疫学的认识,揭示了B细胞在肿瘤微环境中发挥着效应和调节作用。MYC生物学和b细胞功能之间的交叉是相关的,因为MYC对于b细胞成熟是必不可少的,并且在b细胞源性恶性肿瘤(如Burkitt淋巴瘤和弥漫性大b细胞淋巴瘤)中经常失调。我们特别关注myc驱动的致癌信号传导和新兴的基于b细胞的免疫治疗平台之间的交集。这篇综述提出了一个概念性的参考框架,其中MYC被认为不仅是一个增殖驱动因素,而且是一个免疫调节癌基因,可以帮助设计体液治疗策略。本文系统地讨论了抑制MYC的治疗策略,包括BET和CDK抑制剂、MYC- max二聚体的破坏、基于rna的技术、合成致死性方法和新兴的PROTACs。克隆的b细胞群,体内分泌的效应b细胞,CAR-B平台和基于抗体的细胞内靶向是重点领域。综述了迄今为止取得的临床前和临床进展,以及这些疗法成功转化为患者使用所面临的挑战,包括肿瘤异质性、药物递送的局限性和诱导自身免疫的风险。预测未来为myc靶向药物与免疫疗法结合以及使用个性化新抗原驱动的b细胞免疫疗法治疗癌症患者提供了理论依据。总的来说,这些发现支持这样一个概念,即MYC b细胞定向策略将代表一种治疗癌症患者的新方法,通过它们的发展成为新的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced pharmaceutical bulletin
Advanced pharmaceutical bulletin PHARMACOLOGY & PHARMACY-
CiteScore
6.80
自引率
2.80%
发文量
51
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书